Physician profile
Miles Byrd
NPI 1366605073
$478.51
in general payments reported to CMS, 2019-2025
11 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.34 · 2020: $24.81 · 2021: $32.20 · 2022: $50.41 · 2024: $117 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $292.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $197.92 | 2024-2025 | Veozah |
| Roche Diagnostics Corporation | $66.29 | 2019-2020 | |
| Abbvie INC. | $36.07 | 2019-2021 | |
| Boston Scientific Corporation | $30.19 | 2024-2025 | Upsylon |
| Medicem INC. | $25.73 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.68 | 2025 | |
| Organon LLC | $24.68 | 2022 | |
| Millicent US INC | $23.68 | 2025 | Femring, Intrarosa |
| Duchesnay USA Incorporated | $20.59 | 2019 | |
| Exeltis, USA INC. | $15.28 | 2025 | Slynd |
| Medtronic, INC. | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miles Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.